bioMuse is 'a natural history study that aims to track the progression of patients with MSA' (taken from Alterity announcement on 27 Oct 20). So it's just observing patients and recording biomarkers.
ATH434-201 is a Phase 2 randomized, double blinded placebo controlled clinical trial with patients who have early stage MSA
ATH434-202 is a open label biomarker study with more advanced MSA
So the -202 study and bioMuse are similar, but the patients in the -202 study are being treated with ATH434, and the patients in the bioMuse study are not.
The -202 study results were due out at the end of June, now hopefully in the next 4 weeks, and my own personal belief is that the -202 results are important because they will give an indication as to how good (or bad) the results of the -201 study will be when they are announced early next year.
Anyway, that's my understanding.
bioMuse is 'a natural history study that aims to track the...
-
- There are more pages in this discussion • 54 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $18.62M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $886 | 275.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 48 | 56368671 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 125986200 | 26 |
View Market Depth
| Last trade - 11.34am 30/08/2024 (20 minute delay) ? |
| ATH (ASX) Chart |